Description:
This clinical study is going to be done on a type of brain tumor in children called
Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and
have the best outcomes in terms of survival. With the current standard of care for this type
of medulloblastoma it is believed by the investigators that we are over treating the disease
and increasing the long term side effects of these children. Several groups in the world are
testing de-intensification of treatment in this favourable subset of children who experience
long term late side effects of therapy. By reducing the dose to the craniospinal axis and
keeping the total tumor bed dose the same in this study the investigators are expecting to
reduce some of the late side effects of craniospinal irradiation without compromising disease
control and survival.
Title
- Brief Title: Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
- Official Title: Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Subgroup Medulloblastoma.
Clinical Trial IDs
- ORG STUDY ID:
3468
- NCT ID:
NCT04474964
Conditions
- Medulloblastoma, WNT-activated
Purpose
This clinical study is going to be done on a type of brain tumor in children called
Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and
have the best outcomes in terms of survival. With the current standard of care for this type
of medulloblastoma it is believed by the investigators that we are over treating the disease
and increasing the long term side effects of these children. Several groups in the world are
testing de-intensification of treatment in this favourable subset of children who experience
long term late side effects of therapy. By reducing the dose to the craniospinal axis and
keeping the total tumor bed dose the same in this study the investigators are expecting to
reduce some of the late side effects of craniospinal irradiation without compromising disease
control and survival.
Detailed Description
WNT pathway medulloblastomas have the best prognosis amongst all four subgroups with 5-year
overall survival exceeding 90%. Overall medulloblastoma is more common in males. They can
occur at all ages, but, are uncommon in infants. They are mostly uniform in their genetic
aberrations, histological pattern, and clinical presentation. The WNT pathway is involved in
regulating embryonal development in the brain. They are frequently described as having CTNNB1
mutations, nuclear immunohistochemical staining for β-catenin, and monosomy six (deletion of
one copy of chromosome 6 in the tumor). Thus monosomy 6 in conjunction with nuclear β-catenin
accumulation is considered a sensitive and specific marker for WNT pathway medulloblastoma
they are typically located in the midline vermian region filling up the fourth ventricle and
infiltrating the brain stem consistent with their proposed cell of origin from the dorsal
brainstem nuclei. The immediate impact of enhanced understanding of molecular biology has led
to biologically driven next-generation clinical trials in newly diagnosed medulloblastoma.
Given the excellent long-term survival outcomes in WNT-pathway medulloblastoma and potential
for significant late toxicities with currently prevalent doses of CSI (23.4-36Gy), it has
been hypothesized that further reduction of dose or in certain cases avoidance of CSI would
translate into reduction in late morbidity of treatment.
In our first generation FOR-WNT study, the investigators had avoided upfront CSI and treated
the tumor-bed alone with focal conformal radiotherapy in low-risk WNT-pathway medulloblastoma
followed by 6-cycles of adjuvant systemic chemotherapy. However, early experience from our
own study and similar results from another study (primary chemotherapy approach completely
avoiding radiotherapy) suggests an unduly increased risk of relapse - spinal leptomeningeal
or supratentorial if CSI is avoided and local recurrence at primary site too if radiation is
completely avoided. Given the excellent long-term survival outcomes in WNT-pathway
medulloblastoma treated with currently prevalent doses of CSI (23.4-36Gy), presence of
significant late toxicities with such doses, but the increased risk of relapse with avoidance
of CSI and/or local irradiation, the investigators hypothesize that further moderate
reduction of CSI dose to 18Gy/10fx keeping the primary-site dose to 54Gy/30fx would translate
into a meaningful reduction in late morbidity of treatment without compromising disease
control or survival. Thus, the investigators herewith propose the second-generation study
(FOR-WNT 2) to include low-dose CSI (18Gy/10fx) plus tumor-bed boost (36Gy/20fx) for a total
primary site dose of 54Gy/30fx without concurrent chemotherapy followed by standard 6-cycles
of adjuvant systemic chemotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
Low Dose Craniospinal Irradiation | Experimental | WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC >1500 and platelet count >1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol. | |
Eligibility Criteria
Inclusion Criteria:
- Age more than 3 years and less than 16 years.
- Newly diagnosed WNT pathway medulloblastoma.
- Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
- No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF)
assessed by MRI of the brain/spine and lumbar puncture for CSF cytology.
- Fit for initiation of adjuvant treatment within 6-weeks of surgery
Exclusion Criteria:
- Age Less than 3 and more than 16 years.
- Molecular subgroup other than WNT pathway.
- Post-surgery residual disease more than 1.5cm2 on post-operative imaging.
- Evidence of any metastatic disease in the brain, spine or CSF.
- Previous history of radiotherapy or chemotherapy prior to study enrollment.
- Not fit for initiation of adjuvant treatment within 6 weeks of surgery.
- Not willing for consent/assent.
Maximum Eligible Age: | 16 Years |
Minimum Eligible Age: | 3 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Relapse-free survival will be analysed using using the product-limit method of Kaplan-Meier and compared using the log-rank test. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Measure Relapse-free survival in WNT medulloblastoma treated with low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy. Relapse free survival will be calculated from the date of surgery till the first documented clinico-radiological evidence of relapse (recurrence/progression). |
Secondary Outcome Measures
Measure: | Neuro-cognitive function of Participants will be analysed longitudinally over time using linear regression model with time-test for trend |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Neurocognitive Outcome will be assessed using Wechsler scale for children by comparing pre-radiotherapy result with assessment done 3-6 months after radiotherapy, at 1-year post-treatment, and annually thereafter till 5-years. |
Measure: | Growth Hormone levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Serial Serum growth hormone(ng/ml) levels will be done by comparing pre-radiotherapy levels with biochemical assessment done 3-6 months after radiotherapy, at 1-year post-treatment and annually thereafter for 5-years. |
Measure: | Thyroid function levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Serial Thyroid function levels : TSH , T3, T4 levels will be done by comparing pre-radiotherapy levels with biochemical assessment done 3-6 months after radiotherapy, at 1-year post-treatment and annually thereafter for 5-years. |
Measure: | Cortisol levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Serial Cortisol levels (mcg/dl) will be done by comparing pre-radiotherapy levels with biochemical assessment done 3-6 months after radiotherapy, at 1-year post-treatment and annually thereafter for 5-years. |
Measure: | Sex Hormone levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Sex Hormone levels will be done by comparing pre-radiotherapy levels with biochemical assessment done 3-6 months after radiotherapy, at 1-year post-treatment and annually thereafter for 5-years. |
Measure: | Pure tone Audiometry of Participants will be analysed longitudinally over time using linear regression model with time-test for trend. |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Hearing assessment will be done by comparing baseline results with hearing assessment 3-6 months after radiotherapy, at 1-year post-treatment, and annually thereafter for 5-years. |
Details
Phase: | N/A |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Tata Memorial Centre |
Trial Keywords
- WNT medulloblastoma
- low dose craniospinal irradiation
- overall survival
- long term toxicities
Last Updated
September 3, 2020